‘When Cancer Smells Like Love’; New NCI Head; Medicaid Cancer Coverage, or NotJuly 22, 2022
“Nauseating scent of sickness and neglect.” A story of cancer, love, and intimacy. (Washington Post)
NFL star Christian McCaffrey made good on a pledge to help establish The Logan Project, named for a young Carolina Panthers fan who died of leukemia. (Charlotte Observer)
A study from Australia showed that most adults with cancer who did not respond to a primary COVID-19 vaccine series responded to a booster dose. (Cancer)
A small subgroup of patients with pancreatic cancer had “robust and durable” responses to immunotherapy. (Journal for ImmunoTherapy of Cancer)
President Biden has appointed Monica Bertagnolli, MD, of Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, as well as a former president of the American Society of Clinical Oncology, to succeed Ned Sharpless, MD, as director of the National Cancer Institute. (Endpoints News)
MacroGenics announced it has closed a phase II trial of the investigational monoclonal antibody enoblituzumab in combination therapy for head and neck cancer, following the deaths of seven patients enrolled in the trial.
Medicaid coverage does not guarantee access to cancer care at a Commission on Cancer-accredited facility. (Yale School of Medicine, JAMA Network Open)
Merck and AstraZeneca announced that a phase III trial of olaparib (Lynparza), with or without bevacizumab (Avastin), for unresectable/metastatic colorectal cancer ended in futility.
Merck also announced that a phase III clinical trial of pembrolizumab (Keytruda) plus chemoradiation for unresectable locally advanced head and neck cancer did not meet the primary endpoint of event-free survival (EFS).
VBL Therapeutics announced that a phase III trial of the anticancer gene therapy ofranergene obadenovec for platinum-resistant ovarian cancer did not meet the primary endpoints of EFS and overall survival.